NCT02402166 - Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG

SPD489

All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)

Trial Locations (6)

Kennedy Krieger Institute, Baltimore

Duke Child and Family Center, Durham

University of Cincinnati, Cincinnati

Houston Clinical Trials, LLC, Houston

Center For Psychiatry and Behavioral Medicine In, Las Vegas

AVIDA, Newport Beach